Skip to main content
Emcure Pharmaceuticals Limited logo

Emcure Pharmaceuticals Limited — Investor Relations & Filings

Ticker · EMCURE ISIN · INE168P01015 LEI · 335800WYB6OIBY9EOZ42 BSE.NS Manufacturing
Open in API
Filings indexed 201 across all filing types
Latest filing 2024-10-28 Capital/Financing Update
Country IN India
Listing BSE.NS EMCURE

About Emcure Pharmaceuticals Limited

https://www.emcure.com

Emcure Pharmaceuticals Limited is a research-driven global pharmaceutical organization engaged in the development, manufacturing, and marketing of a broad range of differentiated pharmaceutical products. The company maintains a diverse portfolio across several key therapeutic areas, including gynaecology, cardiovascular, oncology, anti-infectives, and HIV/AIDS. With a strong emphasis on research and development, Emcure operates multiple state-of-the-art manufacturing facilities and R&D centers globally. Its business model focuses on complex generics and innovative formulations, serving healthcare needs in over 70 countries. The company is recognized for its vertically integrated operations and commitment to high-quality standards, catering to both regulated and emerging markets worldwide.

Recent filings

Filing Released Lang Actions
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the launch of a new subsidiary, Emcutix Biopharmaceuticals Limited, by Emcure Pharmaceuticals Limited to strengthen its dermatology portfolio. It contains no financial statements, regulatory filings, or detailed financial data. The document is relatively short (3917 characters) and serves as a corporate announcement rather than a report or filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The content is a straightforward press release about a business initiative and subsidiary formation, which aligns best with Capital/Financing Update (CAP) as it relates to company structural and strategic updates involving business expansion and subsidiary formation.
2024-10-28 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a confirmation certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. It confirms the dematerialisation of securities for the quarter ended 30th September 2024. The document is a compliance confirmation letter from Link Intime India Pvt. Ltd. to the company secretary of Emcure Pharmaceuticals Limited. It does not contain financial statements, management discussion, or detailed report data. It is a regulatory compliance communication rather than a financial report or announcement of a meeting or voting results. The document length is short (1952 characters), and it serves as a certification or confirmation letter. According to the rules, such officer certifications or confirmations should be classified as Regulatory Filings (RNS).
2024-10-07 English
Acquisition
Regulatory Filings
2024-10-03 English
Press Release
Regulatory Filings
2024-10-03 English
Trading Window
Regulatory Filings Classification · 95% confidence The document text is extremely short (377 characters) and contains only address and stock exchange listing information for the company EMCURE. There is no substantive financial data, report content, or detailed announcement. It appears to be a brief regulatory or listing-related notice without any report or detailed filing. Given the brevity and lack of report content, this fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-09-26 English
Acquisition
Regulatory Filings
2024-09-13 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.